Mice with a retrovirus-induced immunosuppression (
MAIDS) are susceptible to experimental murine cytomegalovirus (MCMV)
retinitis, but can be rendered resistant to
retinitis by systemic
interleukin-2 (IL-2)
immunotherapy. Experiments were performed to explore the mechanism by which
IL-2 treatment during
MAIDS might restore resistance to MCMV
retinitis. Whereas 80% of untreated
MAIDS mice were susceptible to MCMV
retinitis, none (0%) of IL-2-treated
MAIDS mice developed necrotizing
retinitis. In comparison, 100% of both untreated and IL-2-treated
perforin knockout mice (PKO mice) were susceptible to MCMV
retinitis, and severity of
retinitis and amounts of infectious intraocular MCMV in IL-2-treated PKO mice were equivalent to that in untreated PKO mice. A competitive quantitative RT-PCR assay was used to measure the levels of
perforin mRNA within MCMV-infected eyes of immunologically normal mice, untreated
MAIDS mice, and IL-2-treated
MAIDS mice. Although the level of
perforin mRNA within MCMV-infected eyes of untreated
MAIDS mice susceptible to
retinitis was significantly reduced when compared to the high level found within MCMV-infected eyes of normal mice resistant to
retinitis, systemic treatment of
MAIDS mice with
IL-2 increased
perforin mRNA within MCMV-infected eyes to levels found in normal mice. The ability of
IL-2 treatment to increase intraocular levels of
perforin mRNA diminished with the progression of
MAIDS. Our findings support the hypothesis that systemic
IL-2 immunotherapy during
MAIDS provides protection against MCMV
retinitis by upregulation of
perforin-mediated cytotoxicity used by cytotoxic lymphocytes to kill virus-infected cells.